UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending the reimbursement of Opdivo (nivolumab) in combination with Yervoy (ipilimumab).
Developed by US pharma major Bristol Myers Squibb (NYSE: BMY), the combination is backed for the first line treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer (mCRC).
The NICE recommendation follows a Medicines and Healthcare products Regulatory Agency (MHRA) indication extension of nivolumab-ipilimumab on April 4, 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze